Last updated: September 13, 2026
Brexucabtagene autoleucel, marketed as Tecartus by Kite Pharma and Gilead Sciences, is an autologous CD19-directed CAR-T therapy for adults with relapsed or refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia. Tecartus revenue increased from approximately $91 million in 2020 to about $478 million in 2024, based on Gilead’s reported product sales. Its commercial outlook depends on expansion in adult B-ALL, earlier-line use in mantle cell lymphoma, manufacturing capacity, payer access, and competition from other CAR-T products and bispecific antibodies.
What is brexucabtagene autoleucel and how is Tecartus used?
Brexucabtagene autoleucel is an autologous CAR-T product that genetically modifies a patient’s T cells to recognize CD19-expressing malignant B cells. The therapy is manufactured individually for each patient rather than produced as a standard off-the-shelf biologic.
| Attribute |
Tecartus |
| Active therapy |
Brexucabtagene autoleucel |
| Developer and marketer |
Kite Pharma, a Gilead company |
| Modality |
Autologous CD19 CAR-T cell therapy |
| Primary diseases |
Mantle cell lymphoma; adult B-cell acute lymphoblastic leukemia |
| Administration |
One-time intravenous infusion after lymphodepleting chemotherapy |
| Manufacturing model |
Patient-specific, centralized autologous manufacturing |
| U.S. approval |
July 2020 for mantle cell lymphoma; October 2021 for adult B-ALL |
| Key clinical programs |
ZUMA-2 and ZUMA-3 |
| Main commercial risks |
Manufacturing delays, treatment-center capacity, payer restrictions, toxicity management, and competing therapies |
Tecartus is used after prior systemic treatment. In mantle cell lymphoma, its initial commercial value came from patients with relapsed or refractory disease, particularly after exposure to a Bruton tyrosine kinase inhibitor. In adult B-ALL, Tecartus competes with other salvage regimens and the earlier-approved tisagenlecleucel, marketed as Kymriah.
What are the FDA regulatory milestones for Tecartus?
The FDA granted Tecartus an accelerated approval for adult patients with relapsed or refractory mantle cell lymphoma in July 2020. The approval was based on the ZUMA-2 study, which reported a high overall response rate in heavily pretreated patients, including patients previously treated with a BTK inhibitor (FDA, 2020a).
The FDA expanded Tecartus to adults with relapsed or refractory B-ALL in October 2021. The approval was based on the ZUMA-3 study, which evaluated adults with disease that had relapsed or was refractory to prior therapy (FDA, 2021).
| Milestone |
Date |
Commercial significance |
| Initial U.S. approval in mantle cell lymphoma |
July 2020 |
Established Tecartus in a high unmet-need lymphoma segment |
| U.S. approval in adult B-ALL |
October 2021 |
Added a second hematologic malignancy and expanded manufacturing demand |
| European authorization in mantle cell lymphoma |
2020 |
Added access to major European markets |
| European authorization in adult B-ALL |
2022 |
Expanded the addressable international market |
| Later-line treatment positioning |
Ongoing |
Limits volume but supports high per-patient pricing |
Tecartus has not been approved for first-line treatment of mantle cell lymphoma. That positioning protects the product from direct exposure to the entire newly diagnosed population but limits the available patient pool.
How much revenue does Tecartus generate?
Gilead reports Tecartus sales separately from Yescarta in its annual filings. Reported revenue increased steadily after launch.
| Fiscal year |
Tecartus product sales |
| 2020 |
Approximately $91 million |
| 2021 |
Approximately $247 million |
| 2022 |
Approximately $308 million |
| 2023 |
Approximately $385 million |
| 2024 |
Approximately $478 million |
Sources: Gilead Sciences annual reports and Form 10-K filings (Gilead Sciences, 2021, 2022, 2023, 2024, 2025).
The approximate compound annual growth rate from 2020 through 2024 was more than 50%, although the calculation begins with a partial launch year. Growth from 2023 to 2024 was approximately 24%.
Tecartus remains materially smaller than Yescarta, Gilead’s larger CD19 CAR-T product for large B-cell lymphoma. Gilead’s combined Yescarta and Tecartus cell-therapy revenue reached approximately $2.1 billion in 2024. Yescarta benefits from a larger lymphoma market, broader treatment-line penetration, and more substantial commercial scale.
What drives Tecartus revenue growth?
The main revenue drivers are:
- Increasing use in adult relapsed or refractory B-ALL.
- Continued adoption after BTK inhibitor failure in mantle cell lymphoma.
- Greater physician familiarity with CAR-T referral and treatment.
- Expansion of authorized treatment centers.
- Improved manufacturing turnaround times.
- Reimbursement pathways for high-cost one-time therapies.
- Use in patients who previously received targeted agents, including BTK inhibitors and BCL2-directed treatment.
The main growth constraint is the size of the eligible population. Tecartus is not a broad primary-care product. Each patient requires a referral, leukapheresis, manufacturing, lymphodepletion, infusion, and prolonged monitoring.
When does Tecartus lose regulatory exclusivity?
Tecartus has biologic exclusivity rather than the small-molecule exclusivity structure used for conventional drugs.
The relevant U.S. framework is the Public Health Service Act, under which a reference biologic generally receives 12 years of reference-product exclusivity from first licensure. Because Tecartus was first licensed in 2020, the principal U.S. biologic exclusivity period would generally extend into 2032, subject to the precise statutory treatment of the product’s original licensure and any regulatory determinations.
Orphan-drug exclusivity is also relevant:
| Indication |
U.S. approval |
Potential seven-year orphan exclusivity endpoint |
| Mantle cell lymphoma |
July 2020 |
July 2027 |
| Adult B-ALL |
October 2021 |
October 2028 |
Orphan exclusivity blocks approval of the same drug for the same disease or condition during the applicable period, subject to statutory exceptions. It does not prevent all competing therapies, including different CAR-T constructs, bispecific antibodies, antibody-drug conjugates, or small-molecule agents.
There is no single Orange Book patent expiration date for Tecartus. The Orange Book primarily covers approved small-molecule drugs and certain listed products, while biological products are tracked through the Purple Book and related FDA exclusivity records.
What patents protect brexucabtagene autoleucel?
Tecartus is protected by a layered intellectual-property estate rather than one conventional product patent. The relevant categories include:
- CAR construct and antigen-binding-domain patents.
- T-cell engineering and gene-transfer patents.
- Vector and transduction-process patents.
- Cell expansion and activation patents.
- Manufacturing and quality-control patents.
- Cryopreservation and shipping methods.
- Treatment protocols and patient-selection claims.
- Platform patents associated with Kite’s CAR-T technology.
The commercial strength of the estate depends on claim scope and enforceability. A patent covering a specific CAR construct may be more important than a broad process patent if competing products use similar CD19-binding domains. Manufacturing patents can still create operational barriers, but they are less likely to block a competitor that develops an independent production process.
What formulations are protected by Tecartus patents?
Tecartus is not primarily differentiated by a conventional formulation patent. Its product protection is more closely tied to:
- The engineered cellular composition.
- The genetic construct.
- The manufacturing process.
- The release specifications.
- The administration protocol.
Cellular products also face practical manufacturing barriers that are difficult to reproduce even when a competing company avoids direct patent infringement. These barriers include chain-of-identity controls, viral-vector supply, closed-system processing, release testing, site accreditation, and clinical-grade logistics.
What method-of-use patents protect Tecartus?
Method-of-use protection can cover treatment of defined patient populations, such as adults with relapsed or refractory mantle cell lymphoma after prior BTK inhibitor exposure or adults with relapsed or refractory B-ALL. Such claims may support enforcement against a specific use but do not necessarily prevent sale of a competing CD19 CAR-T product for another indication.
Public FDA materials do not establish a single, definitive patent expiration date that would determine U.S. generic or biosimilar entry for Tecartus. The practical exclusivity position is a combination of biologic exclusivity, orphan exclusivity, construct patents, manufacturing patents, and regulatory barriers.
Are there Paragraph IV challenges to Tecartus?
No conventional Paragraph IV pathway applies to Tecartus because it is a biologic, not a small-molecule drug approved under an abbreviated new drug application.
A future competitor would generally pursue a biosimilar application under section 351(k) of the Public Health Service Act or seek approval as a separate biologic under section 351(a). A biosimilar applicant would face product-specific analytical, manufacturing, clinical, and interchangeability requirements.
The first meaningful U.S. competition is more likely to come from alternative CD19 CAR-T products than from a biosimilar version of Tecartus. Autologous CAR-T products are difficult to copy because each therapy incorporates a distinct manufacturing process and patient-specific cell product.
Which companies are challenging Tecartus commercially?
Tecartus faces competition from several classes of therapy.
| Competitor |
Company |
Modality |
Principal overlap |
| Breyanzi |
Bristol Myers Squibb |
CD19 CAR-T |
Mantle cell lymphoma and other B-cell malignancies |
| Kymriah |
Novartis |
CD19 CAR-T |
Adult B-ALL |
| Yescarta |
Gilead/Kite |
CD19 CAR-T |
Broader B-cell lymphoma infrastructure and physician reach |
| Carvykti |
Johnson & Johnson and Legend Biotech |
BCMA CAR-T |
Competes for CAR-T capacity and treatment-center resources |
| Abecma |
Bristol Myers Squibb and 2seventybio |
BCMA CAR-T |
Competes for manufacturing slots and cell-therapy infrastructure |
| Columvi |
Roche |
CD20xCD3 bispecific antibody |
Relapsed or refractory B-cell lymphoma |
| Epkinly |
AbbVie and Genmab |
CD20xCD3 bispecific antibody |
Relapsed or refractory large B-cell lymphoma |
| Lunsumio |
Roche |
CD20xCD3 bispecific antibody |
Relapsed or refractory follicular lymphoma |
| Jaypirca |
Eli Lilly |
BTK inhibitor |
Mantle cell lymphoma and other B-cell malignancies |
Breyanzi is the most direct newer CAR-T competitor in mantle cell lymphoma. Bispecific antibodies are a separate competitive threat because they can be administered without leukapheresis and individualized cell manufacturing. Their simpler logistics may appeal to hospitals and patients even when CAR-T offers a potentially durable response.
How does Tecartus compare with Breyanzi and Kymriah?
Tecartus has a distinct commercial position.
| Factor |
Tecartus |
Breyanzi |
Kymriah |
| Core antigen |
CD19 |
CD19 |
CD19 |
| Key overlap |
MCL and adult B-ALL |
MCL and B-cell lymphomas |
B-ALL and B-cell lymphomas |
| Manufacturing |
Autologous |
Autologous |
Autologous |
| Main advantage |
Established MCL and adult B-ALL use |
Expanding lymphoma label and competitive efficacy profile |
Earlier market entry and pediatric/young-adult B-ALL position |
| Main limitation |
Later-line positioning and complex logistics |
Manufacturing and treatment-center constraints |
Competitive pressure from newer CAR-T therapies |
Tecartus has the strongest strategic position in adult B-ALL among its approved indications when evaluated against its own label and commercial infrastructure. In mantle cell lymphoma, the market is becoming more competitive as Breyanzi expands and targeted therapies move into earlier lines.
What is the risk of generic or biosimilar entry?
Near-term generic entry risk is low. A conventional generic cannot substitute for an autologous CAR-T product. The relevant risk is competition from:
- A biosimilar or highly similar CD19 CAR-T product.
- A separately approved CD19 CAR-T with comparable efficacy.
- An allogeneic or off-the-shelf CAR-T therapy.
- Bispecific antibodies.
- Next-generation targeted therapies.
- Improved salvage regimens that reduce referrals to CAR-T centers.
The most important competitive risk is not a low-cost copy. It is a therapy with simpler administration, faster availability, lower inpatient burden, or more predictable reimbursement.
What patent litigation affects Tecartus?
Tecartus is exposed to the broader CAR-T patent environment, including litigation involving CAR constructs, T-cell engineering, viral vectors, and manufacturing methods. CAR-T patent disputes can affect product development even when they do not name Tecartus directly because the same technology categories are used across competing products.
The most relevant legal framework for a future biosimilar dispute would be the Biologics Price Competition and Innovation Act, including the patent-information exchange process often called the patent dance. A 351(a) competitor could face conventional patent litigation outside the abbreviated biosimilar framework.
No major public settlement agreement establishing early market entry for a Tecartus biosimilar is identified in the cited FDA and Gilead materials. Kite’s acquisition by Gilead in 2017 remains the central licensing and ownership event for the product’s commercial platform. Gilead acquired Kite for approximately $11.9 billion, bringing Kite’s CAR-T technology and pipeline into Gilead (Gilead Sciences, 2017).
What manufacturing and geographic barriers affect Tecartus?
Tecartus requires a coordinated manufacturing network. The commercial process includes leukapheresis, shipment of patient cells, T-cell activation and genetic modification, expansion, quality testing, cryopreservation, return shipment, lymphodepletion, and infusion.
The main barriers are:
- Manufacturing-slot availability.
- Vein-to-vein time.
- Patient eligibility changes during production.
- Failed or delayed manufacturing.
- Viral-vector supply.
- Treatment-center accreditation.
- Intensive monitoring for cytokine release syndrome and neurologic toxicity.
- Reimbursement for inpatient and outpatient care.
- Cross-border transport and customs requirements.
The United States is the primary revenue market. Europe provides additional volume but has more fragmented reimbursement and treatment-center infrastructure. Geographic expansion increases demand but also raises logistics costs and regulatory complexity.
What is the future financial trajectory for Tecartus?
Tecartus should continue to grow, but the rate is likely to moderate from its early launch phase. The most credible growth path is steady expansion in adult B-ALL and continued use in relapsed or refractory mantle cell lymphoma.
The financial trajectory has four scenarios:
| Scenario |
Commercial outcome |
| Base case |
Continued annual growth from B-ALL and MCL, offset by competition from Breyanzi and bispecific antibodies |
| Upside case |
Earlier-line MCL use, stronger B-ALL penetration, improved manufacturing throughput, and broader reimbursement |
| Downside case |
Reduced CAR-T referral rates, manufacturing constraints, price pressure, and migration to bispecific antibodies |
| Disruption case |
Successful off-the-shelf CAR-T or a substantially easier outpatient therapy reduces demand for autologous products |
Tecartus is strategically valuable to Gilead because it shares manufacturing, treatment-center, and commercial infrastructure with Yescarta. Its revenue contribution is smaller than Yescarta’s, but the two products create operating leverage across the cell-therapy platform.
Key Takeaways
- Tecartus generated approximately $478 million in sales in 2024, up from about $385 million in 2023.
- Its approved indications are adult relapsed or refractory mantle cell lymphoma and adult relapsed or refractory B-ALL.
- U.S. orphan exclusivity may extend to 2027 for MCL and 2028 for B-ALL.
- General biologic reference-product exclusivity from the 2020 license date points toward the early 2030s.
- Paragraph IV challenges do not apply because Tecartus is a biologic.
- Biosimilar risk is limited in the near term because autologous CAR-T products are difficult to replicate.
- Breyanzi is the most direct CAR-T competitor in mantle cell lymphoma.
- Bispecific antibodies present the largest practical threat because they avoid individualized cell manufacturing.
- Tecartus patent protection is layered across CAR constructs, manufacturing, vectors, cell processing, and methods of use.
- Manufacturing capacity, reimbursement, and treatment-center access are as important commercially as patent duration.
FAQs
Can Tecartus be replaced by a conventional generic drug?
No. Tecartus is an autologous biologic cell therapy. A conventional small-molecule generic cannot substitute for it.
Is Tecartus interchangeable with Kymriah?
No. Both target CD19, but they are separate products with different constructs, manufacturing processes, labels, clinical data, and regulatory status.
Does Tecartus have an Orange Book listing?
No conventional Orange Book listing governs Tecartus. Biologic exclusivity and patent information are assessed through the Purple Book, FDA biologic records, and applicable patent databases.
What is the biggest commercial threat to Tecartus?
The largest practical threat is a competing therapy with simpler logistics, particularly a bispecific antibody or off-the-shelf cell therapy that avoids leukapheresis and individualized manufacturing.
Is Tecartus revenue exposed to Gilead’s Yescarta manufacturing network?
Yes. Tecartus and Yescarta use overlapping corporate, treatment-center, and cell-therapy infrastructure. Capacity allocation and manufacturing efficiency can affect both products.
References
-
Food and Drug Administration. (2020a). FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2021). FDA approves brexucabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2020b). Tecartus prescribing information. U.S. Department of Health and Human Services.
-
Gilead Sciences, Inc. (2017). Gilead Sciences to acquire Kite Pharma for $11.9 billion. Investor relations release.
-
Gilead Sciences, Inc. (2021). 2020 annual report. U.S. Securities and Exchange Commission.
-
Gilead Sciences, Inc. (2022). 2021 annual report. U.S. Securities and Exchange Commission.
-
Gilead Sciences, Inc. (2023). 2022 annual report. U.S. Securities and Exchange Commission.
-
Gilead Sciences, Inc. (2024). 2023 annual report. U.S. Securities and Exchange Commission.
-
Gilead Sciences, Inc. (2025). 2024 annual report. U.S. Securities and Exchange Commission.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.
